期刊文献+

强直性脊柱炎患者血清OPG和sRANKL表达及意义

Expression and significance of serum OPG and sRANKL in patients with ankylosing spondylitis
原文传递
导出
摘要 目的探讨强直性脊柱炎(AS)患者血清护骨素(OPG)和可溶性核因子κB受体活化因子配体(sRANKL)表达及意义。方法采用ELISA检测44例AS患者与44例正常对照组血清OPG和sRANKL的水平,分析其与AS的相关性。结果血清sRANKL水平及sRANKL/OPG比值在AS组均显著高于正常对照组(P<0.01)。有外周关节受累的AS患者血清OPG水平显著高于无外周关节受累的AS患者(P<0.01)。最佳截断点上血清sRANKL(>5.24pmol/L)诊断AS的敏感性、特异性和正确率分别为54.5%、84.1%、69.3%,而sRANKL/OPG比值(>0.63)均为75.0%。结论 OPG/RANKL系统可能参与AS的发病和外周关节受累;血清sRANKL/OPG比值可以用于AS的辅助诊断。 Objective To investigate the expression and significance of serum osteoprotegerin(OPG)and soluble receptor activator of nuclear factor-кB ligand(sRANKL) in patients with ankylosing spondylitis(AS).Methods Serum OPG and sRANKL levels were determined by ELISA in 44 AS patients(group A) and matched 44 healthy controls(group C).Results Compared with group C,serum sRANKL and ratio of sRANKL to OPG were higher in group A than those in group C(P0.01),which were higher in the cases with peripheral joint involvement than those without(P0.01).According to Youden index of ROC curve,the diagnostic sensitivity,specificity and accuracy of cut-off point of serum sRANKL(5.24 pmol/L) were 54.5%,84.1%,and 69.3%,respectively,which of sRANKL/OPG ratio(0.63) were all 75.0%.Conclusion OPG/RANKL system may be involved in the pathogenesis of AS and peripheral joint injury.Serum sRANKL/OPG ratio may be taken as an auxiliary diagnosis indicator of AS.
作者 罗红玉
出处 《江苏医药》 CAS CSCD 北大核心 2011年第23期2770-2772,共3页 Jiangsu Medical Journal
关键词 强直性脊柱炎 护骨素 核因子ΚB受体活化因子配体 Ankylosing spondylitis Osteoprotegerin Receptor activator of nuclear factor-кB ligand
  • 相关文献

参考文献9

  • 1樊秋贵,郭钧,杨民.OPG RANKL RANK等因子在类风湿关节炎患者血清及滑膜液中的变化及意义[J].中华风湿病学杂志,2007,11(1):38-40. 被引量:24
  • 2Chen CH, Chen HA, Liao HT, et al. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis:OPG is associated with poor physical mobility and reflects systemic inflammation [J]. Clin Rhoumatol, 2010,29 (10): 1155-1161.
  • 3Sarma PK, Misra R,Aggarwal A. Elevated serum receptor activator of NFkappaB ligand (RANKL),osteoprotegerin (OPG), matrix metalloproteinase (MMP) 3, and ProMMP1 in patients with juvenile idiopathic arthritis[J]. Clin Rheumatol, 2008,27 (3) : 289-294.
  • 4van der Linden S,Valkenburg HA,Cats A. Evaluation of diag nostic criteria for ankylosing spondylitis. A proposal for modi fication of the New York criteria [J]. Arthritis Rheum, 1984, 27(4):361-368.
  • 5Lorenzo J, Horowitz M, Choi Y. Osteoimmunology:interacons of the bone and immune system[J]. Endoer Rev, 2008,29(4): 403-440.
  • 6Vandooren B, Cantaert T, Noordenbos T, et al. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation[J]. Arthritis Rheum, 2008, 58 (3) : 718- 729.
  • 7Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS) [J]. Rheumatology (Oxford), 2006,45 (10) : 1197-1200.
  • 8Oelzner P, Franke S, Lehmann G, et al. Soluble receptor activator of NFkappaB ligand and osteoprotegerin in rheumatoid arthritis-relationship with bone mineral density, disease activity and bone turnover [J]. Clin Rheumatol, 2007,26(12): 2127- 2135.
  • 9赵伟,黄烽.护骨素在强直性脊柱炎外周关节骨质破坏病理机制中的作用[J].中华风湿病学杂志,2005,9(6):329-333. 被引量:17

二级参考文献31

  • 1Toussirot E, Ricard-Blum S, Dumoulin G, et al. Relationship between urinary pyridinium cross-links, disease activity and disease suhsets of ankylosing spondylitis. Rheumatol (Oxford), 1999, 38:21-27.
  • 2Toussirot E, Michel F, Auge B, et al. Bone mass, body composition and bone ultrasound measurements in ankylosing spondylitis.Arthritis Rheum, 1999, 42(Suppl): 356.
  • 3Bernecker PM, Aringer M, et al. Ankylosing spondylitis,arthritis, and reactive arthritis show increased bone rebut differ with regard to bone formation. J Rheumatol,2002,29:1430-1436.
  • 4Maksymowych WP. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol, 2000, 27: 2295-3301.
  • 5Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am, 1998,24:697-736.
  • 6Bekker PJ, Holloway D, Nakanishi A, et al. Osteoprotegerin has potent and sustained anti-resorptive activity in postmenopausal women. J Bone Miner Res, 1999, 14(Suppl 1):1190.
  • 7Hotbauer LC, Khosla S, Dunstan CR, et al. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res, 2000, 15: 2-12.
  • 8Mori H, Kitazawa R, Maeda S, et al. RANK ligand, RANK, and OPG expression in type Ⅱ collagen-induced arthritis mouse.Histochem Cell Biol, 2002, 117: 283-292.
  • 9Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.Arthritis Rheum, 2000, 43: 250-258.
  • 10Yukio S, Thomas P, Peter K, et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum, 2000,43: 2523-2530.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部